• Growth targets: Management expects Q4 revenue to increase 9% to 10% over Q3, contributing to 20% growth in H2 over H1, and guides for over 20% total business growth in FY27 as US and European markets recover.
• Margin trajectory: Standalone EBITDA margins are projected at 26% to 28% and consolidated margins at 24.5% to 25%, with plans to lift margins in newly acquired orthopedic and cardiology businesses toward 20% over the next one to two years.
• Cost headwinds: Surging crude oil and freight rates present a potential 100 to 200 basis points margin risk, though the company's 68% to 69% gross margins and pricing power offer a buffer.
• Chinese competition: The company is seeking government protection against Chinese manufacturers who circumvent tariffs by dumping medical devices into India via FTA partner countries such as Vietnam, Malaysia, and Thailand.
• Domestic expansion: Driven by hospital bed additions, expanding insurance coverage, and the replacement of multinational products, Poly Medicure projects its Indian business to sustain roughly 25% annual growth supported by a pipeline of over 100 products.